By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Clinical Research is the subject of a report. According to news reporting out of New Delhi, India, by NewsRx editors, research stated, "Oxidative stress and inflammatory damage play an important role in cerebral ischemic pathogenesis and may represent a target for treatment. The development of new strategies for enhancing drug delivery to the brain is of great importance in diagnostics and therapeutics of central nervous diseases."
Our news journalists obtained a quote from the research from Hamdard University, "The present study examined the hypothesis that intranasal delivery of nanoformulation of curcuminoids would reduce oxidative stress-associated brain injury after middle cerebral artery occlusion (MCAO). The rats were subjected to 2 h of MCAO followed by 22 h reperfusion, after which the grip strength, locomotor activity was performed. The effects of treatment in the rats were assessed by grip strength, locomotor activity and biochemical studies (glutathione peroxidase, glutathione reductase, lipid peroxidation, superoxide dismutase, and catalase) in the brain. Pretreatment with polymeric N-isopropyl acryl amide (PNIPAM) nanoparticles formulation of all three curcuminoids (curcumin (Cur), demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC)) at doses (100 mu g/kg body weight) given intranasally was effective in bringing significant changes on all the parameters. While nanoformulation of curcumin at a dose of 100 mu g/kg body weight was most active in the treatment of cerebral ischemia as compared to others nanoformulation of curcuminoids."
According to the news editors, the research concluded: "The potency of antioxidant activity significantly decreased in the order of PNIPAM nanoformulation of Cur > DMC >> BDMC, thus suggesting the critical role of methoxy groups on the phenyl ring."
For more information on this research see: A comparative study of PNIPAM nanoparticles of curcumin, demethoxycurcumin, and bisdemethoxycurcumin and their effects on oxidative stress markers in experimental stroke. Protoplasma, 2013;250(6):1327-1338. Protoplasma can be contacted at: Springer Wien, Sachsenplatz 4-6, PO Box 89, A-1201 Wien, Austria. (Springer - www.springer.com; Protoplasma - www.springerlink.com/content/0033-183x/)
Our news journalists report that additional information may be obtained by contacting N. Ahmad, Hamdard Univ, Fac Sci, Dept. of Chem, New Delhi 110062, India. Additional authors for this research include S. Umar, M. Ashafaq, M. Akhtar, Z. Iqbal, M. Samim and F.J. Ahmad (see also Clinical Research).
Keywords for this news article include: Asia, India, Alkanes, Curcumin, New Delhi, Catechols, Treatment, Hydrocarbons, Diarylheptanoids, Clinical Research, Organic Chemicals, Experimental Stroke, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC